drugset / Trial / NCT00527150

Multiple Dose, Dose Escalation Study of Varenicline Controlled Release Formulation in Adult Smokers

NCT00527150

Phase 1 Completed 48 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of escalating multiple oral doses of varenicline AMT 8 controlled release formulation for 14 days in adult smokers.

Timeline

Start
2007-10
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Varenicline Small molecule 1.8 mg Oral
Subject Varenicline Small molecule 2.4 mg Oral
Subject Varenicline Small molecule 3 mg Oral

Indications

No indication recorded.